BIO
An optimised Plasmid DNA platform to accelerate the path to clinic and commercialisation
Speaker:
Jing Zhu, Vice President, Nucleic Acid & Viral Vector Technology
The journey from laboratory innovation to clinical application poses formidable challenges. Scalability, regulatory compliance, and technical complexities in plasmid DNA-based therapeutics are challenges that demand specialised expertise.
Overcoming these hurdles necessitates partnering with an expert in the field to optimise processes and ensure seamless progression toward clinical and commercial success.
ReciBioPharm promises a commitment to innovation, offering expertise optimising plasmid DNA production to meet diverse therapeutic needs, ensuring scalability, purity, and consistency throughout the development lifecycle.
With continuous investment in facilities and novel technologies that optimise plasmid DNA platforms, we offer comprehensive solutions tailored to individual project requirements. This plasmid CDMO expertise and infrastructure expedite the development trajectory of biologics, propelling them swiftly from early-stage discovery to clinical trials and eventual commercialisation.
In our new webinar, “An optimised Plasmid DNA platform to accelerate the path to clinic and commercialisation”, we discuss:
- Assessing key parameters of the upstream process to achieve high titer while maintaining desired integrity
- Customising the downstream process to address the different needs of supercoil plasmid and linear isoform
- A platform approach with integrated processes and analytical toolboxes to accelerate plasmid development to manufacturing
Fill out your information below to watch the webinar.